Enduring Material

Psound Bytes: The Challenge of Treating Nail Psoriasis
View Activity Info
Enter Basic User Info
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
 
 
National Psoriasis Foundation

6600 SW 92nd Ave., Suite 300
Portland, OR 97223-7195
General Information
Thursday, June 4, 2020 - Friday, June 3, 2022
National Psoriasis Foundation
Virtual Conference Room
Psound Bytes: Difficult to Treat Series
National Psoriasis Foundation
Objectives
  • Understand the pathology of psoriatic disease, its manifestations and related comorbidities, indicating why it’s important to treat the disease to target.
  • Develop strategies for treating “difficult to treat” forms of psoriasis, including palmoplantar, guttate, genital, oral, nail and scalp psoriasis.
  • Select appropriate therapies for moderate to severe psoriatic disease based on current evidence for efficacy, safety and adherence, particularly with regard to difficult to treat cases.
Presentations and Speakers
Psound Bytes: The Challenge of Treating Nail Psoriasis
  • April W Armstrong, MD
Available Credits/Points
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.
From diagnosis to therapy options nail psoriasis can be a challenge to treat. Listen as leading dermatologist and NPF Medical Board Member, Dr. April Armstrong, Director of the Psoriasis Program, Dept. of Dermatology at Keck School of Medicine, USC, addresses the challenges and offers tips to help manage nail psoriasis. For more information read the JPPA article "Nail Psoriasis: A Review of Treatment Options" https://journals.sagepub.com/doi/pdf/10.1177/247553031016.00405.
Disclosure Statements
Andi Agnew, NPF Staff/Planning Committee, has disclosed no relevant financial relationships with commercial interests.
Speakers:
April W Armstrong, MD has disclosed a relevant financial relationship with a commercial interest in the last 12 months:
  • Abbvie, Bristol-Myers Squibb, Lilly, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme - Consulting
  • Abbvie, Bristol-Myers Squibb, Lilly, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme - Contracted Research
  • Dermavant, Modernizing Medicine, Ortho Dermatologics, Pfizer, Science 37, Sun Pharma - Consulting
  • Dermira, Kyowa Hakko Kirin, UCB - Contracted Research
This activity is commercially supported by an educational grant from Lilly.
Accreditation Statement
  • The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Test Information
0 %
6/2/2020
Continue to Enduring Material